Lotemax

Lotemax

loteprednol

Manufacturer:

Bausch & Lomb

Distributor:

Zuellig
/
Agencia Lei Va Hong
Full Prescribing Info
Contents
Loteprednol etabonate.
Description
Lotemax also contains the following inactive ingredients: Edetate disodium, glycerin, povidone, purified water and tyloxapol. Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH to 5.3-5.6. Benzalkonium chloride 0.01% is added as a preservative.
The suspension is essentially isotonic with a tonicity of 250-310 mOsmol/kg.
Loteprednol etabonate is a white to off-white powder.
Loteprednol etabonate is chloromethyl-17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate. Its molecular formula is C24H31ClO7 and has a molecular weight of 466.96.
Action
Topical anti-inflammatory corticosteroid for ophthalmic use.
Pharmacology: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary and fibroblast proliferation, deposition of collagen and scar formation associated with inflammation.
There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called as lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation eg, prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure.
Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites.
Results from a bioavailability study in normal volunteers established that plasma levels of loteprednol etabonate and δ1-cortienic acid etabonate (PJ 91), its primary inactive metabolite, were below the limit of quantitation (1 ng/mL) at all sampling times. The results were obtained following the ocular administration of 1 drop in each eye of 0.5% loteprednol etabonate 8 times daily for 2 days or 4 times daily for 42 days. This study suggests that limited (<1 ng/mL) systemic absorption occurs with Lotemax.
Clinical Studies: Postoperative Inflammation: Placebo-controlled clinical studies demonstrated that Lotemax is effective for the treatment of anterior chamber inflammation as measured by cell and flare.
Giant Papillary Conjunctivitis: Placebo-controlled clinical studies demonstrated that Lotemax was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of treatment and continuing for up to 6 weeks while on treatment.
Seasonal Allergic Conjunctivitis: A placebo-controlled clinical study demonstrated that Lotemax was effective in reducing the signs and symptoms of allergic conjunctivitis during peak periods of pollen exposure.
Uveitis: Controlled clinical studies of patients with uveitis demonstrated that Lotemax was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in intraocular pressure (IOP) (≥10 mm HG) was 1% with Lotemax and 6% with prednisolone acetate 1%.
Indications/Uses
Treatment of postoperative inflammation following ocular surgery.
Treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe eg, allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
Dosage/Direction for Use
Shake vigorously before using.
Postoperative Inflammation: Apply 1-2 drops of Lotemax into the conjunctival sac of the operated eye(s) 4 times daily beginning 24 hrs after surgery and continuing throughout the first 2 weeks of the postoperative period.
Steroid-Responsive Disease Treatment: Apply 1-2 drops of Lotemax into the conjunctival sac of the affected eye(s) 4 times daily. During the initial treatment within the 1st week, the dosing may be increased up to 1 drop every hr, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (see Precautions).
Contraindications
Lotemax, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
Individuals with known or suspected hypersensitivity to any of the ingredients of Lotemax and to other corticosteroids.
Special Precautions
For ophthalmic use only.
The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification eg, slit lamp biomicroscopy and, where appropriate, fluorescein staining.
If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.
If Lotemax is used for ≥10 days, intraocular pressure should be monitored even though it may be difficult in children and uncooperative patients.
Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungal invasion must be considered in any persistent corneal ulceration where a steroid has been used or is being used. Fungal cultures should be taken when appropriate.
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Steroids should be used with caution in the presence of glaucoma.
Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask infection of enhance existing infection.
Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.
The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
Carcinogenicity, Mutagenicity & Impairment of Fertility: Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma tk assay or in a chromosome aberration test in human lymphocytes, or in vivo in the single-dose mouse micronucleus assay.
Treatment of male and female rats with up to 50 mg/kg/day and 25 mg/kg/day of loteprednol etabonate, respectively, (600 and 300 times the maximum clinical dose, respectively) prior to and during mating did not impair fertility in either gender.
Use in pregnancy: Pregnancy Category C: Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no observed effect level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose).
Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at ≥5 mg/kg/day doses, and cleft palate and umbilical hernia at ≥50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥50 mg/kg/day).
Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity. Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses ≥5 mg/kg/day.
Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation. The NOEL for these effects was 5 mg/kg/day.
Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.
Use in lactation: It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production or cause other untoward effects. Caution should be exercised when Lotemax is administered to a nursing woman.
Use in children: Safety and effectiveness in pediatric patients have not been established.
Use In Pregnancy & Lactation
Use in pregnancy: Pregnancy Category C: Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no observed effect level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose).
Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at ≥5 mg/kg/day doses, and cleft palate and umbilical hernia at ≥50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥50 mg/kg/day).
Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity. Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses ≥5 mg/kg/day.
Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation. The NOEL for these effects was 5 mg/kg/day.
Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.
Use in lactation: It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production or cause other untoward effects. Caution should be exercised when Lotemax is administered to a nursing woman.
Adverse Reactions
Reactions associated with ophthalmic steroids include elevated intraocular pressure which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens eg, herpes simplex and the perforation of the globe where there is thinning of the cornea or sclera.
Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2-0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection and photophobia. Other ocular adverse reactions occurring in <5% of patients include conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillae and uveitis. Some of these events were similar to the underlying ocular disease being studied.
Non-ocular adverse reactions occurred in <15% of patients. These include headache, rhinitis and pharyngitis.
In a summation of controlled, randomized studies of individuals treated for ≥28 days with loteprednol etabonate, the incidence of significant elevation of intraocular pressure (≥10 mm Hg) was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients receiving prednisolone acetate 1% and 0.5% (3/583) among patients receiving placebo.
Caution For Usage
Information for Patients: Lotemax is sterile when packaged. Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the suspension.
If pain develops and redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician.
As with all ophthalmic preparations containing benzalkonium chloride, patients should be advised not to wear soft contact lenses when using Lotemax.
Storage
Store between 15-25°C (59-77°F) in an upright position. Do not freeze.
MIMS Class
ATC Classification
S01BA14 - loteprednol ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
Presentation/Packing
Eye drops (sterile) 0.5% (5 mg/mL) x 5 mL.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in